Pliant Therapeutics, Inc. is a clinical-stage biotechnology company. Co. is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Its lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of ?vß6 and ?vß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). Co. has initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF. It has also developed PLN-1474, a small molecule, selective inhibitor of ?vß1 integrin for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. We show 23 historical shares outstanding datapoints in our coverage of PLRX's shares outstanding history.
Understanding the changing numbers of PLRX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like PLRX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching PLRX by allowing them to research PLRX shares outstanding history
as well as any other stock in our coverage universe. |
Free PLRX Email Alerts:
Video: Shares Outstanding Importance
